These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 6373212

  • 21. Estramustine phosphate as primary therapy for metastatic prostate cancer. Preliminary results of the University of Wisconsin trial.
    Benson RC.
    Urology; 1984 Jun; 23(6 Suppl):69-72. PubMed ID: 6375084
    [No Abstract] [Full Text] [Related]

  • 22. Effect of estramustine phosphate on plasma testosterone during treatment of carcinoma of prostate.
    Kjaer TB, Nilsson T, Madsen PO.
    Urology; 1975 Jun; 5(6):802-4. PubMed ID: 1136096
    [Abstract] [Full Text] [Related]

  • 23. Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer.
    Perry CM, McTavish D.
    Drugs Aging; 1995 Jul; 7(1):49-74. PubMed ID: 7579781
    [Abstract] [Full Text] [Related]

  • 24. A randomized double blind crossover trial of diethylstilbestrol (DES) and estramustine phosphate (Emcyt) for stage D prostatic carcinoma.
    Benson RC, Gill GM, Cummings KB.
    Semin Oncol; 1983 Sep; 10(3 Suppl 3):43-5. PubMed ID: 6364366
    [No Abstract] [Full Text] [Related]

  • 25. Oral estramustine phosphate (NSC-89199) in the treatment of advanced (stage D) carcinoma of the prostate.
    Mittelman A, Shukla SK, Welvaart K, Murphy GP.
    Cancer Chemother Rep; 1975 Sep; 59(1):219-23. PubMed ID: 1093669
    [Abstract] [Full Text] [Related]

  • 26. Comparison of estramustine phosphate, methotrexate and cis-platinum in patients with advanced, hormone refractory prostate cancer.
    Loening SA, Beckley S, Brady MF, Chu TM, deKernion JB, Dhabuwala C, Gaeta JF, Gibbons RP, McKiel CF, McLeod DG, Pontes JE, Prout GR, Scardino PT, Schlegel JU, Schmidt JD, Scott WW, Slack NH, Soloway MS, Murphy GP.
    J Urol; 1983 May; 129(5):1001-6. PubMed ID: 6343629
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Estramustine phosphate in the treatment of advanced prostatic cancer.
    Küss R, Khoury S, Richard F, Fourcade F, Frantz P, Capelle JP.
    Br J Urol; 1980 Feb; 52(1):29-33. PubMed ID: 7426949
    [Abstract] [Full Text] [Related]

  • 29. Results of another trial of chemotherapy with and without hormones in patients with newly diagnosed metastatic prostate cancer.
    Murphy GP, Huben RP, Priore R.
    Urology; 1986 Jul; 28(1):36-40. PubMed ID: 3523938
    [Abstract] [Full Text] [Related]

  • 30. Treatment of stage D hormone-resistant carcinoma of the prostate with estramustine phosphate.
    Benson RC, Wear JB, Gill GM.
    J Urol; 1979 Apr; 121(4):452-4. PubMed ID: 439216
    [Abstract] [Full Text] [Related]

  • 31. Change in white cell count during treatment of advanced cancer of the prostate with estramustine phosphate and with stilboestrol.
    Daponte D, Sylvester R, De Pauw M, Fryszman A, Smith RM, Smith PH.
    Br J Urol; 1983 Aug; 55(4):408-12. PubMed ID: 6349745
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. French multicenter study on the use of estramustine phosphate versus diethylstilbestrol.
    Hauchecorne J.
    Prog Clin Biol Res; 1987 Aug; 243B():229-34. PubMed ID: 3309983
    [No Abstract] [Full Text] [Related]

  • 34. Estramustine phosphate in prostate cancer. EORTC experience: preliminary results of Protocol 30762.
    Smith PH, Robinson M, Richards B, Suciu S, De Pauw M, Sylvester R, Denis L.
    Urology; 1984 Jun; 23(6 Suppl):64-8. PubMed ID: 6375083
    [No Abstract] [Full Text] [Related]

  • 35. Estramustine phosphate compared with diethylstilbestrol. A randomized, double-blind, crossover trial for stage D prostate cancer.
    Benson RC, Gill GM.
    Am J Clin Oncol; 1986 Aug; 9(4):341-51. PubMed ID: 3529921
    [Abstract] [Full Text] [Related]

  • 36. The use of estramustine phosphate in the modern management of advanced prostate cancer.
    Ravery V, Fizazi K, Oudard S, Drouet L, Eymard JC, Culine S, Gravis G, Hennequin C, Zerbib M.
    BJU Int; 2011 Dec; 108(11):1782-6. PubMed ID: 21756277
    [Abstract] [Full Text] [Related]

  • 37. A comparison of estramustine phosphate versus cis-platinum alone versus estramustine phosphate plus cis-platinum in patients with advanced hormone refractory prostate cancer who had had extensive irradiation to the pelvis or lumbosacral area.
    Soloway MS, Beckley S, Brady MF, Chu TM, deKernion JB, Dhabuwala C, Gaeta JF, Gibbons RP, Loening SA, McKiel CF, McLeod DG, Pontes JE, Prout GR, Scardino PT, Schlegel JU, Schmidt JD, Scott WW, Slack NH, Murphy GP.
    J Urol; 1983 Jan; 129(1):56-61. PubMed ID: 6338251
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Hormone changes in patients with prostatic carcinoma during treatment with estramustine phosphate.
    Fosså SD, Fosså J, Aakvaag A.
    J Urol; 1977 Dec; 118(6):1013-8. PubMed ID: 926240
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.